Roflumilast Powders for Chronic Obstructive Pulmonary Disease: Formulation Design and the Influence of Device, Inhalation Flow Rate, and Storage Relative Humidity on Aerosolization

Roflumilast is currently administered orally to control acute exacerbations in chronic obstructive pulmonary disease (COPD). However, side effects such as gastrointestinal disturbance and weight loss have limited its application. This work aimed to develop an inhalable roflumilast formulation to red...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmaceutics 2021-08, Vol.13 (8), p.1254, Article 1254
Hauptverfasser:	Momin, Mohammad A. M., Adhikari, Bishal Raj, Sinha, Shubhra, Larson, Ian, Das, Shyamal C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aerosols Aluminum Chronic obstructive pulmonary disease Drug dosages dry powder Ethanol Gas flow L-leucine Life Sciences & Biomedicine Particle size Pharmacology & Pharmacy Phase transitions roflumilast Science & Technology Solvents trehalose
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!